WallStSmart

DaVita HealthCare Partners Inc (DVA)vsThe Ensign Group Inc (ENSG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 152% more annual revenue ($13.84B vs $5.49B). ENSG leads profitability with a 6.9% profit margin vs 5.7%. DVA appears more attractively valued with a PEG of 0.74. DVA earns a higher WallStSmart Score of 67/100 (B-).

DVA

Strong Buy

67

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22

ENSG

Buy

60

out of 100

Grade: C+

Growth: 8.0Profit: 6.0Value: 4.0Quality: 6.0
Piotroski: 4/9Altman Z: 2.15
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVASignificantly Overvalued (-15.7%)

Margin of Safety

-15.7%

Fair Value

$124.67

Current Price

$227.99

$103.32 premium

UndervaluedFair: $124.67Overvalued
ENSGSignificantly Overvalued (-39.8%)

Margin of Safety

-39.8%

Fair Value

$151.60

Current Price

$176.13

$24.53 premium

UndervaluedFair: $151.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA4 strengths · Avg: 9.0/10
Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

Debt/EquityHealth
-17.5010/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.748/10

Growing faster than its price suggests

EPS GrowthGrowth
43.5%8/10

Earnings expanding 43.5% YoY

ENSG1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
17.3%8/10

17.3% revenue growth

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
5.7%3/10

5.7% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

ENSG3 concerns · Avg: 3.7/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Profit MarginProfitability
6.9%3/10

6.9% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on Return on Equity, Debt/Equity, PEG Ratio. PEG of 0.74 suggests the stock is reasonably priced for its growth.

Bull Case : ENSG

The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 17.3% demonstrates continued momentum.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : ENSG

The primary concerns for ENSG are PEG Ratio, P/E Ratio, Profit Margin.

Key Dynamics to Monitor

DVA profiles as a value stock while ENSG is a growth play — different risk/reward profiles.

DVA carries more volatility with a beta of 0.88 — expect wider price swings.

ENSG is growing revenue faster at 17.3% — sustainability is the question.

DVA generates stronger free cash flow (219M), providing more financial flexibility.

Bottom Line

DVA scores higher overall (67/100 vs 60/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

The Ensign Group Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.

Want to dig deeper into these stocks?